Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Australasian Journal of Neuroscience
Volume 32 (2022): Issue 1 (May 2022)
Open Access
Rituximab in the treatment of Pembrolizumab induced Myasthenia Gravis
Jessica C. O’Keeffe
Jessica C. O’Keeffe
,
Nadia Deborah Friedman
Nadia Deborah Friedman
and
Sujith Ayyappan
Sujith Ayyappan
| Jul 11, 2022
Australasian Journal of Neuroscience
Volume 32 (2022): Issue 1 (May 2022)
About this article
Previous Article
Next Article
Abstract
Article
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Published Online:
Jul 11, 2022
Page range:
5 - 11
DOI:
https://doi.org/10.21307/ajon-2022-002
© 2022 Jessica C. O’Keeffe et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Jessica C. O’Keeffe
Department of General Medicine, University Hospital Geelong
Victoria, Australia
Nadia Deborah Friedman
Department of Infectious Diseases, University Hospital Geelong
Victoria, Australia
Sujith Ayyappan
Department of Neurology, University Hospital Geelong
Victoria, Australia